Ryan advises clients on intellectual property issues in connection with transactions, including mergers and acquisitions, in- and out-licensing relationships, and venture financings. He evaluates the intellectual property portfolios of target companies, as well as potentially blocking third-party intellectual property.
Ryan works with clients in the biotechnology and biopharmaceutical industries on a wide range of intellectual property issues, including patent portfolio strategy, patent opinions, and freedom-to-operate analysis. Prior to joining the Intellectual Property Transactions group, Ryan prosecuted life sciences patent applications for over eleven years.
Prior to joining the firm, Ryan completed a Ph.D. in genetics from Harvard University, where his graduate work focused on zebrafish genetic cancer models and chemical genetic approaches in the laboratory of Professor Leonard Zon.
- Represented a biotechnology company drafting and prosecuting a broad patent portfolio in the U.S. and around the world.
- Represented a venture capital firm in connection with an investment in a biotechnology company.
- Represented a biopharmaceutical company in a patent interference resulting in a victory for the client.
- Presenter, “Implications of Recent Decisions, Legislation, PTO Guidance on Diligence Analysis,” Strafford Publishing Webinar (March 3, 2020)
- Moderator, “New Developments in the Courts and Congress Influencing IP Due Diligence,” American Conference Institute’s Third Annual Summit on Life Sciences IP Due Diligence (November 15, 2019)
- JD, New York University School of Law, 2010
- PhD (Genetics), Harvard University, 2006
- BS (Molecular and Cell Biology), summa cum laude, University of Connecticut, 1998; Phi Beta Kappa, Honors program